1Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).UK Prospective Diabetes Study (UKPDS) Group.Lancet,1998,352:837-853.
2Boland E,Monsod T,Delucia M,et al.Limitations of conventional methods of self-monitoring of blood glucose:lessons learned from 3 days of continuous glucose sensing in pediatric patients with type1 diabetes.Diabetes Care,2001,24:1858-1862.
4Gross TM, Bode BW, Einhorn D, et al. Performance evaluation of the MiniMed continuous glucose monitoring system during patient home use. Diabetes Technol Ther,2000,2:49-56.
5Mastrototaro J. The MiniMed continuous glucose monitoring system(CGMS). J Pediatr Endocriol Metab, 1999,12:751-758.
6Bode BW, Gross TM, Thornton KR, et al. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin. Diabetes Res Clin Pract, 1999,46:183-190.
7Boyne MS, Silver DM, Kaplan J, et al. Timing of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensor. Diabetes, 2003, 52:2790-2794.
8Steil GM, Rebrin K, Mastrototaro J, et al. Determination of plasma glucose during rapid glucose excursions with a subcutaneous glucose sensor. Diabetes Technol Ther,2003,5:27-31.
9Kaufman FR, Carpenter S, Gibson LC, et al. A pilot study of the continuous glucose monitoring system. Diabetes Care, 2001,24:2030-2034.
10Rohlfing CL, England JD, Wiedmeyer HM, et al. Defining the relationship between plasma glucose and HbA1c. Diabetes Care, 2002,25:275-278.
9Suarez PW,Rajotte RV,Mosmann TR,et al.Both CD4+ and CD8+T cells in syngenic islet grafts in NOD mice produce interferon-gramma during beta-cell destruction[J].Diabetes,1996,45(10):1 350.
10Takahanshin M,Masuyam QJ,Ikeda U,et al.Effects of endogenous endothelial interleukin-8 on neutrophil migration across an endothelial monolayer[J].Cardiovasc Res,1995,29(5):670.
